Literature DB >> 20167809

Temozolomide and MGMT forever?

Michael Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20167809      PMCID： PMC2940592          DOI： 10.1093/neuonc/noq016

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

Review 1.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors:  Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal:  Nat Rev Neurol       Date:  2009-12-08       Impact factor: 42.937

2.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.

Authors:  Alba A Brandes; Enrico Franceschi; Alicia Tosoni; Stefania Bartolini; Antonella Bacci; Raffaele Agati; Claudio Ghimenton; Sergio Turazzi; Andrea Talacchi; Miran Skrap; Gianluca Marucci; Lorenzo Volpin; Luca Morandi; Stefano Pizzolitto; Marina Gardiman; Alvaro Andreoli; Fabio Calbucci; Mario Ermani
Journal:  Neuro Oncol       Date:  2010-02-01       Impact factor: 12.300

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

Authors:  Antje Wick; Jörg Felsberg; Joachim P Steinbach; Ulrich Herrlinger; Michael Platten; Britta Blaschke; Richard Meyermann; Guido Reifenberger; Michael Weller; Wolfgang Wick
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

6.  Rechallenge with temozolomide in patients with recurrent gliomas.

Authors:  Antje Wick; Christina Pascher; Wolfgang Wick; Tanja Jauch; Michael Weller; Ulrich Bogdahn; Peter Hau
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

7.  Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Authors:  James R Perry; Philippe Rizek; Rosemary Cashman; Meredith Morrison; Tara Morrison
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

8.  Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

Authors:  Doo-Sik Kong; Jung-Il Lee; Jong Hyun Kim; Sung Tae Kim; Won Seog Kim; Yeon-Lim Suh; Seung Myung Dong; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2010-01-11       Impact factor: 12.300

9.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

10.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

Authors:  A A Brandes; A Tosoni; G Cavallo; R Bertorelle; V Gioia; E Franceschi; M Biscuola; V Blatt; L Crinò; M Ermani
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640
  10 in total
  1 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.